Virginia Ruth Sanzone - 07 Mar 2026 Form 4 Insider Report for ICU MEDICAL INC/DE (ICUI)

Role
VP, General Counsel
Signature
By: Paula Darbyshire, Attorney-in-Fact For: Virginia Sanzone
Issuer symbol
ICUI
Transactions as of
07 Mar 2026
Net transactions value
$0
Form type
4
Filing time
09 Mar 2026, 16:18:31 UTC
Previous filing
12 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sanzone Virginia Ruth VP, General Counsel 951 CALLE AMANECER, SAN CLEMENTE By: Paula Darbyshire, Attorney-in-Fact For: Virginia Sanzone 09 Mar 2026 0001669639

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICUI Common Stock Options Exercise +2,348 +43% $0.000000* 7,804 07 Mar 2026 Direct F1
transaction ICUI Common Stock Tax liability -1,297 -17% $132.00* 6,507 07 Mar 2026 Direct
transaction ICUI Common Stock Options Exercise +23,917 +368% $0.000000* 30,424 08 Mar 2026 Direct F2
transaction ICUI Common Stock Tax liability -13,221 -43% $132.00* 17,203 08 Mar 2026 Direct
transaction ICUI Common Stock Options Exercise +3,189 +19% $0.000000* 20,392 08 Mar 2026 Direct F1
transaction ICUI Common Stock Tax liability -1,762 -8.6% $132.00* 18,630 08 Mar 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICUI Common Stock Options Exercise -2,348 -17% $0.000000* 11,075 07 Mar 2026 Common Stock 2,348 Direct F1, F3, F4, F5
transaction ICUI Common Stock Options Exercise -3,189 -29% $0.000000* 7,886 08 Mar 2026 Common Stock 3,189 Direct F1, F3, F4, F5
transaction ICUI Performance Shares Options Exercise -23,917 -100% $0.000000* 0 08 Mar 2026 Common Stock 23,917 $0.000000 Direct F2, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are Restricted Stock Units.
F2 Represents the settlement of performance stock units granted on 3/8/2024. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 250% of target, resulting in the acquisition of the shares reported herein.
F3 There is neither a purchase price nor an exercise price for the Restricted Stock Units.
F4 One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date.
F5 These are restricted stock units that fully vest 3 years from the grant date.
F6 These Securities are Performance-based Restricted Stock Units (PRSU).
F7 There is neither a purchase price nor an exercise price for the PRSUs.